<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421603</url>
  </required_header>
  <id_info>
    <org_study_id>#5368</org_study_id>
    <secondary_id>R01DA022217</secondary_id>
    <nct_id>NCT00421603</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence</brief_title>
  <acronym>TACT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) and Topiramate for the Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety
      and efficacy of Adderall-XR (ER-MAS) and topiramate in the treatment of cocaine dependence.
      Since both of these medications have independently shown promise in helping with cocaine
      abuse we are proposing that together they may be even more successful in the treatment of
      cocaine abuse. We plan to enroll 120 subjects in a 14-week trial. The primary objective of
      the study is to determine the efficacy of ER-MAS and topiramate in promoting cocaine
      abstinence among cocaine-dependent patients. This study includes free treatment for cocaine
      dependence that includes medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To determine the efficacy of ER-MAS and topiramate in promoting cocaine
      abstinence among cocaine-dependent patients.

      Primary Hypothesis: The proportion of participants achieving sustained cocaine abstinence
      (via urine toxicology) for three consecutive weeks during the study will be significantly
      greater for the combined pharmacotherapies group compared to the placebo group.

      Hypothesis 2: The proportion of urine samples negative for cocaine metabolites will be
      greater in the combined pharmacotherapies group compared to the placebo group.

      Hypothesis 3: The pattern of cocaine use (amount of cocaine used per day in dollars and the
      number of using days per week), as measured by the time-line follow-back method, will show a
      greater reduction in use for the combined pharmacotherapies group compared to the placebo
      group.

      Specific Aim 2: To determine the effect of ER-MAS and topiramate on cocaine craving among
      cocaine-dependent patients.

      Hypothesis 4: Cocaine craving symptoms will be reduced to a greater degree in the combined
      pharmacotherapies group compared to the placebo group.

      Specific Aim 3: To explore a set of related secondary outcomes (treatment retention, global
      functioning, HIV risk behavior) as well as moderators and mediators potentially reflective of
      mechanism of action.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back</measure>
    <time_frame>3 weeks of abstinence during 14 weeks of trial or for length of participation</time_frame>
    <description>Cocaine use was assessed by using urine toxicology confirmed self-report. Self-reported cocaine use data was collected for each day of the study period by the Time Line Follow Back. Urine samples were collected three times per week. A week was considered abstinence if no cocaine use was self reported during that week and if all urine samples collected that week were negative for cocaine. If a patient achieved three continuous weeks of abstinence based on this criteria they were considered cocaine abstinent in terms of this outcome measure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Adderall-XR and Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adderall-XR (60 mg/day) and Topiramate (300mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall-XR and Topiramate</intervention_name>
    <description>Adderall-XR 60mg/day and Topiramate 300mg/day</description>
    <arm_group_label>Adderall-XR and Topiramate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18-60 who meet DSM-IV criteria for current cocaine
             dependence (DSM-IV-TR).

          2. Used cocaine at least four days in the past month, with at least weekly cocaine use.

          3. Must have a Body Mass Index (BMI) &gt; 18 kg/m2

          4. Alcohol Breathalyzer (BraC) at consent of &lt; 0.04%

          5. Individuals must be capable of giving informed consent and capable of complying with
             study procedures.

          6. Women of child bearing age will be included in the study provided that they are not
             pregnant, based on the results of a blood pregnancy test drawn at the time of
             screening. They must also agree to use a method of contraception with proven efficacy
             and agree not to become pregnant during the study. To confirm this, blood pregnancy
             tests will be repeated monthly. Women will be provided a full explanation of the
             potential dangers of pregnancy while on the study medication. If a woman becomes
             pregnant, the study medication will be discontinued.

        Exclusion Criteria:

          1. Meets DSM-IV-TR criteria for bipolar disorder, Schizophrenia, or any psychotic
             disorder other than transient psychosis due to drug abuse

          2. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR
             supported by the SCID-I/P that in the investigator's judgment are unstable or would be
             disrupted by study medication or are likely to require pharmacotherapy during the
             study period.

          3. Individuals with current major depressive disorder.

          4. Individuals physiologically dependent on any other drugs (excluding nicotine or
             cannabis) which require medical intervention.

          5. Individuals with current psycho stimulant abuse or dependence.

          6. Individuals with current suicidal risk.

          7. Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG or history of cardiac symptoms.

          8. Unstable physical disorders which might make participation hazardous such as
             uncontrolled hypertension (SBP &gt; 150, DBP&gt; 90, or HR &gt; 100 when sitting quietly),
             acute hepatitis (patients with chronic mildly elevated transaminases &lt; 3x upper limit
             of normal are acceptable), or uncontrolled diabetes.

          9. Individuals with a history of seizures

         10. History of allergic reaction to candidate medication (amphetamine and/or ER-MAS or
             topiramate).

         11. Women who are pregnant or nursing.

         12. Use of carbonic anhydrase inhibitors*

         13. History of glaucoma, kidney stones*

         14. History of failure to respond to a previous Adequate trial of either candidate
             medication for Cocaine dependence

         15. Currently being prescribed psychotropic medication by another physician (other than
             sleep medication)

         16. Individuals who are legally mandated (e.g., to avoid incarceration, monetary or other
             penalties, etc.) to participate in substance abuse treatment program -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances R Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu/</url>
    <description>Substance Treatment and Research Service of Columbia University</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <results_first_submitted>December 13, 2012</results_first_submitted>
  <results_first_submitted_qc>January 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2013</results_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Drug Abuse (NIDA)</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Director of Substance Use Disorder</investigator_title>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Adderall</keyword>
  <keyword>Topiramate</keyword>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited by local advertising (internet, print, radio, television, and subway) or by clinical referrals in the New York City metropolitan area between January 2007 and February 2010.</recruitment_details>
      <pre_assignment_details>Prior to group assignment patients participated in a one week placebo lead-in.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adderall-XR and Topiramate</title>
          <description>Adderall-XR doses were titrated over two weeks to a maximum dose of 60 mg daily and topiramate doses were titrated over six weeks to a maximum dose of 150 mg twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo daily dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28">Completed all 14 week sof trial</participants>
                <participants group_id="P2" count="30">Completed all 14 week sof trial</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adderall-XR and Topiramate</title>
          <description>Adderall-XR doses were titrated over two weeks to a maximum dose of 60 mg daily and topiramate doses were titrated over six weeks to a maximum dose of 150 mg twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo daily dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="8.2"/>
                    <measurement group_id="B2" value="42.4" spread="8.9"/>
                    <measurement group_id="B3" value="42.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back</title>
        <description>Cocaine use was assessed by using urine toxicology confirmed self-report. Self-reported cocaine use data was collected for each day of the study period by the Time Line Follow Back. Urine samples were collected three times per week. A week was considered abstinence if no cocaine use was self reported during that week and if all urine samples collected that week were negative for cocaine. If a patient achieved three continuous weeks of abstinence based on this criteria they were considered cocaine abstinent in terms of this outcome measure.</description>
        <time_frame>3 weeks of abstinence during 14 weeks of trial or for length of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adderall-XR and Topiramate</title>
            <description>Adderall-XR doses were titrated over two weeks to a maximum dose of 60 mg daily and topiramate doses were titrated over six weeks to a maximum dose of 150 mg twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back</title>
          <description>Cocaine use was assessed by using urine toxicology confirmed self-report. Self-reported cocaine use data was collected for each day of the study period by the Time Line Follow Back. Urine samples were collected three times per week. A week was considered abstinence if no cocaine use was self reported during that week and if all urine samples collected that week were negative for cocaine. If a patient achieved three continuous weeks of abstinence based on this criteria they were considered cocaine abstinent in terms of this outcome measure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The dichotomous primary outcome was analyzed using logistic regression with independent predictors: treatment (MAS-ER and topiramate vs. placebo) and adjusted for baseline severity of cocaine use (total number of cocaine use days in the 28 days prior to randomization).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>All analyses were conducted on the intent-to-treat sample of all randomized patients. All statistical tests were 2-tailed and employed at a significance level of 5%, unless otherwise stated. The original sample size of 120 patients was chosen to ensure sufficient power (at least 80%) of a two-sided test with level of significance Î±=0.05 for detecting difference between the two experimental treatments with respect to the percentage of subjects who achieve continuous 3-weeks abstinence.</non_inferiority_desc>
            <p_value>=.05</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during 14 weeks of trial or length of participants participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adderall-XR and Topiramate</title>
          <description>Adderall-XR doses were titrated over two weeks to a maximum dose of 60 mg daily and topiramate doses were titrated over six weeks to a maximum dose of 150 mg twice daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo daily dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>substance-induced mood syndrome</sub_title>
                <description>One participant in the MAS-ER and topiramate group developed a substance-induced mood syndrome and required hospitalization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>residential drug treatment</sub_title>
                <description>The other participant in the placebo group voluntarily discontinued study participation during the final week of the trial and entered a residential substance abuse treatment center.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Irritable</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased/decreased appetite</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The two-arm placebo controlled design does not allow us to address whether both medications are necessary for efficacy. Potential limited treatment masking that occurred when giving two medications with distinctive adverse effect profiles.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Daniel Brooks</name_or_title>
      <organization>NYSPI</organization>
      <phone>212-740-3205</phone>
      <email>brooksd@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

